Drugs galore

Posted on

As if to reinforce the point in today's video, I noticed this in the FT yesterday:

GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, including cancer and HIV drugs, sending shares up as much as 6 per cent on Wednesday.

Shareholders will also benefit from higher dividends, with the payout set to rise to 61p per share for the 2024 financial year, up from 58p last year, after the drugmaker reported an increase in annual sales. The FTSE 100 group raised its long-term annual sales forecast to more than £40bn by 2031, up from a previous forecast of more than £38bn.

As I argue in the video, curing diseases provides no benefit to a drug company. Creating drugs that have to be taken for life to manage a disease - which continues to afflict the sufferer - does, however, provide a massive boost to their profitability. I think GSK proves the point.

In my opinion, big pharma really does not want to cure people. Managing them in their sickness is much more profitable for them. No wonder NHS costs are increasing.


Thanks for reading this post.
You can share this post on social media of your choice by clicking these icons:

There are links to this blog's glossary in the above post that explain technical terms used in it. Follow them for more explanations.

You can subscribe to this blog's daily email here.

And if you would like to support this blog you can, here:

  • Richard Murphy

    Read more about me

  • Support This Site

    If you like what I do please support me on Ko-fi using credit or debit card or PayPal

  • Archives

  • Categories

  • Taxing wealth report 2024

  • Newsletter signup

    Get a daily email of my blog posts.

    Please wait...

    Thank you for sign up!

  • Podcast

  • Follow me

    LinkedIn

    LinkedIn

    Mastodon

    @RichardJMurphy

    BlueSky

    @richardjmurphy.bsky.social